A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa).

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1115 ◽

2021 ◽

pp. clincanres.1115.2021

Author(s):

Debashis Sarker ◽

Nancy A. Dawson ◽

Ana M. Aparicio ◽

Tanya B Dorff ◽

Allan J. Pantuck ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Finding ◽

Open Label ◽

Castration Resistant ◽

Finding Study ◽

Label Dose ◽

A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America

The Journal of Urology ◽

10.1016/j.juro.2008.07.033 ◽

2008 ◽

Vol 180 (5) ◽

pp. 1986-1992 ◽

Cited By ~ 67

Author(s):

Marc Gittelman ◽

Peter J. Pommerville ◽

Bo-Eric Persson ◽

Jens-Kristian Jensen ◽

Tine Kold Olesen ◽

...

Keyword(s):

Prostate Cancer ◽

North America ◽

Phase Ii ◽

Dose Finding ◽

Open Label ◽

Randomized Phase Ii ◽

Finding Study ◽

MP-08.21: A multicentre, randomised one year dose-finding study of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, in prostate cancer patients

Urology ◽

10.1016/j.urology.2007.06.325 ◽

2007 ◽

Vol 70 (3) ◽

pp. 83-84

Author(s):

M. Gittelman ◽

P.J. Pommerville ◽

B.E. Persson ◽

T. Kold Olesen

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Gnrh Receptor ◽

Dose Finding ◽

Receptor Blocker ◽

Releasing Hormone ◽

Finding Study ◽

Dose Finding Study ◽

Gonadotrophin Releasing Hormone ◽

One Year

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2017.01.024 ◽

2017 ◽

Vol 76 ◽

pp. 36-44 ◽

Cited By ~ 29

Author(s):

Christophe Massard ◽

Kim Nguyen Chi ◽

Daniel Castellano ◽

Johann de Bono ◽

Gwenaelle Gravis ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Dose Finding ◽

Phase Ib ◽

Castration Resistant ◽

Finding Study ◽

Editorial Comment on: Degarelix: a Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dose-Finding Study in the Treatment of Prostate Cancer

European Urology ◽

10.1016/j.eururo.2008.04.066 ◽

2008 ◽

Vol 54 (4) ◽

pp. 814

Author(s):

Patrick J. Bastian

Keyword(s):

Prostate Cancer ◽

Editorial Comment ◽

Gnrh Receptor ◽

Gonadotropin Releasing Hormone ◽

Dose Finding ◽

Receptor Blocker ◽

Phase 2 ◽

Releasing Hormone ◽

Finding Study ◽

Editorial Comment on: Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dose-Finding Study in the Treatment of Prostate Cancer

European Urology ◽

10.1016/j.eururo.2008.04.067 ◽

2008 ◽

Vol 54 (4) ◽

pp. 815

Author(s):

Peter Whelan

Keyword(s):

Prostate Cancer ◽

Editorial Comment ◽

Gnrh Receptor ◽

Gonadotropin Releasing Hormone ◽

Dose Finding ◽

Receptor Blocker ◽

Phase 2 ◽

Releasing Hormone ◽

Finding Study ◽

Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44]

European Journal of Cancer ◽

10.1016/j.ejca.2017.05.003 ◽

2017 ◽

Vol 81 ◽

pp. 242 ◽

Cited By ~ 2

Author(s):

Christophe Massard ◽

Kim Nguyen Chi ◽

Daniel Castellano ◽

Johann de Bono ◽

Gwenaelle Gravis ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Dose Finding ◽

Phase Ib ◽

Castration Resistant ◽

Finding Study ◽

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyx011 ◽

2017 ◽

Vol 47 (5) ◽

pp. 438-446 ◽

Cited By ~ 2

Author(s):

Seiichiro Ozono ◽

Taiji Tsukamoto ◽

Seiji Naito ◽

Yasuo Ohashi ◽

Takeshi Ueda ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Maintenance Dose ◽

Japanese Patients ◽

Dose Finding ◽

Efficacy And Safety ◽

Dosing Regimen ◽

Finding Study ◽

Phase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K)β inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC)

Annals of Oncology ◽

10.1093/annonc/mdx370.009 ◽

2017 ◽

Vol 28 ◽

pp. v273 ◽

Cited By ~ 1

Author(s):

P. Rescigno ◽

J. de Bono ◽

A. Aparicio ◽

S. Chowdhury ◽

P. Twardowski ◽

...

Keyword(s):

Prostate Cancer ◽

Dose Finding ◽

Open Label ◽

Castration Resistant ◽

Finding Study ◽

Label Dose ◽

Dose Finding Study ◽

Phosphoinositide 3 Kinase ◽

Male Subjects

969 poster A dose-finding study of IORT after radical prostatectomy (RP) in prostate cancer

Radiotherapy and Oncology ◽

10.1016/s0167-8140(04)82836-6 ◽

2004 ◽

Vol 73 ◽

pp. S409

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Dose Finding ◽

Finding Study ◽